Safety Profile
Information not yet available for this ingredient profile.
Interactions
Information not yet available for this ingredient profile.
Evidence and Scientific Findings
Ingredient Overview
Wax moth larva (Galleria mellonella) tincture is a traditional folk remedy popular in Russia/Eastern Europe, claimed to have immunomodulatory, adaptogenic, and antimycobacterial properties. It contains ceramidase, lipase, and protease enzymes, as well as fatty acids and amino acids. Human clinical evidence is very limited and largely anecdotal. No randomised controlled trials support its therapeutic claims. Allergy to insect proteins is a contraindication. Potential for heavy metal and microbial contamination with unregulated preparations. Should be used with caution and only from verified, tested sources.
Biological and Chemical Classification
- Scientific Name
- Galleria mellonella
Mechanism of Action
Information not yet available for this ingredient profile.
Clinical Evidence of Effectiveness
Information not yet available for this ingredient profile.
Pharmacokinetics
Information not yet available for this ingredient profile.
Recommended Dosage
Information not yet available for this ingredient profile.
SETI — Scientific Evidence Transparency Index
Executive Summary — Ingredient Assessment
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or RCT)
- Main clinical benefit observed: Specialty
- Evidence consistency: High consistency across studies (100%)
- No significant safety signals identified in the reviewed literature.
The available scientific evidence for Wax Moth Larva Extract indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.
Total SETI Score
High risk| Evidence quality | 10/40 |
| Evidence consistency | 20/20 |
| Safety signals | 0/20 |
| Study recency | 10/10 |
| Evidence transparency | 10/10 |
Evidence Summary
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or systematic review)
- 0 studies identified benefits or no safety concern (GREEN)
- 10 studies reported limited or advisory safety evidence (YELLOW)
Evidence Policy
Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.
Last updated: 06 აპრ 2026, 12:09
Evidence Distribution
-
Observational / other LOW evidence YELLOWAntimicrobial effects and mechanism of action of carboxymethyl chitosan-loaded silver ion complexes against drug-resistant Aspergillus fumigatus. ↗Jin L et al.. Antimicrobial effects and mechanism of action of carboxymethyl chitosan-loaded silver ion complexes against drug-resistant Aspergillus fumigatus.. J Microbiol. 2026. PMID:41937392.PMID 41937392 ↗Journal J MicrobiolYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41937392/
-
Observational / other LOW evidence YELLOWComparative profiling of virulence determinants, capsular serotypes, and antimicrobial resistance in hypervirulent and classical Klebsiella pneumoniae isolates from liver abscess patients. ↗Liu J et al.. Comparative profiling of virulence determinants, capsular serotypes, and antimicrobial resistance in hypervirulent and classical Klebsiella pneumoniae isolates from liver abscess patients.. Int Microbiol. 2026. PMID:41926004.PMID 41926004 ↗Journal Int MicrobiolYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41926004/
-
Observational / other LOW evidence YELLOWCampylobacter jejuni strains isolated in Brazil have important virulence related genes and survive to different stress conditions. ↗Frazu00e3o MR et al.. Campylobacter jejuni strains isolated in Brazil have important virulence related genes and survive to different stress conditions.. Braz J Microbiol. 2026. PMID:41920224.PMID 41920224 ↗Journal Braz J MicrobiolYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41920224/
-
Observational / other LOW evidence YELLOWDifferential roles of Scj1 and Djp1, two DnaJ homologs, in virulence, cell wall integrity, and multi-stress tolerance of Beauveria bassiana. ↗Hu W et al.. Differential roles of Scj1 and Djp1, two DnaJ homologs, in virulence, cell wall integrity, and multi-stress tolerance of Beauveria bassiana.. Antonie Van Leeuwenhoek. 2026. PMID:41920222.PMID 41920222 ↗Journal Antonie Van LeeuwenhoekYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41920222/
-
Observational / other LOW evidence YELLOWTrans-cinnamaldehyde triggers stringent response-mediated virulence attenuation in pathogenic Escherichia coli. ↗Karczewska M et al.. Trans-cinnamaldehyde triggers stringent response-mediated virulence attenuation in pathogenic Escherichia coli.. Biomed Pharmacother. 2026. PMID:41916131.PMID 41916131 ↗Journal Biomed PharmacotherYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41916131/
-
Observational / other LOW evidence YELLOWCharacterization of a ST412-K57 colistin-resistant hypervirulent Klebsiella pneumoniae strain of chicken origin. ↗Xu Q et al.. Characterization of a ST412-K57 colistin-resistant hypervirulent Klebsiella pneumoniae strain of chicken origin.. J Antimicrob Chemother. 2026. PMID:41914556.PMID 41914556 ↗Journal J Antimicrob ChemotherYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41914556/
-
Observational / other LOW evidence YELLOWDual-Peptide Nanoplatform: Mesoporous Silica Nanoparticles Functionalized With a Cell-Penetrating Peptide and Loaded With Rationally Designed Antimicrobial Peptides for Tuberculosis Therapy. ↗Carnero Canales CS et al.. Dual-Peptide Nanoplatform: Mesoporous Silica Nanoparticles Functionalized With a Cell-Penetrating Peptide and Loaded With Rationally Designed Antimicrobial Peptides for Tuberculosis Therapy.. Adv Healthc Mater. 2026. PMID:41906540.PMID 41906540 ↗Journal Adv Healthc MaterYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41906540/
-
Observational / other LOW evidence YELLOWDesign and optimization of the surfactant mixture ratio for oleic acid-based ophthalmic nanoemulsions prepared by the HPH technology - feasibility study for… ↗Gawin-Mikou0142ajewicz A et al.. Design and optimization of the surfactant mixture ratio for oleic acid-based ophthalmic nanoemulsions prepared by the HPH technology - feasibility study for clotrimazole as a model drug.. Eur J Pharm Biopharm. 2026. PMID:41903825.PMID 41903825 ↗Journal Eur J Pharm BiopharmYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41903825/
-
Observational / other LOW evidence YELLOWPhenotypic and Transcriptomic Characterization of Host-Associated Responses in a Carbapenem-Resistant Klebsiella pneumoniae ST11 Clinical Isolate. ↗Hua M et al.. Phenotypic and Transcriptomic Characterization of Host-Associated Responses in a Carbapenem-Resistant Klebsiella pneumoniae ST11 Clinical Isolate.. Pathogens. 2026. PMID:41901735.PMID 41901735 ↗Journal PathogensYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41901735/
-
Observational / other LOW evidence YELLOWExtracellular Vesicles from the Probiotic Yeast Pichia kudriavzevii: Proteomic Characterization and Modulation of Immune and Defense Responses in an Induced Inflammation Model… ↗Maione A et al.. Extracellular Vesicles from the Probiotic Yeast Pichia kudriavzevii: Proteomic Characterization and Modulation of Immune and Defense Responses in an Induced Inflammation Model of Intestinal Epithelial Cells.. Nutrients. 2026. PMID:41901087.PMID 41901087 ↗Journal NutrientsYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41901087/
Score Transparency
0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.
Method: Q = number of approved references ÷ 10 (capped at 1.0)
Limited — mostly case reports or animal studies
Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.
Mixed or neutral — roughly equal benefit and risk signals
Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.
One or more monitoring-level safety signals active
Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.
Final GIRI Score for Wax Moth Larva Extract. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
Full methodology & data sources
The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.
- References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
- Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
- Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
- Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.
Risk Level Classification
Based on available regulatory signals and scientific evidence, this ingredient presents a moderate safety concern. Caution is advised, particularly at high doses or in sensitive populations.
0–3.0
3.0–5.5
5.5–7.5
7.5–10
The score pin shows exactly where this ingredient falls on the fixed risk scale.
What drove the Moderate classification for Wax Moth Larva Extract
A score of 3.5 places this ingredient in the Moderate band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
0 approved references.
Limited — mostly case reports or animal studies (Level 4–5).
Neutral or mixed — benefit and risk signals roughly balanced.
No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.
No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).
How are the Low / Moderate / High / Critical thresholds defined?
The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:
| Level | Score | Meaning |
|---|---|---|
| LOW | 0.0 – 2.9 | Sparse or predominantly beneficial evidence. No active safety alerts. |
| MODERATE | 3.0 – 5.4 | Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups. |
| HIGH | 5.5 – 7.4 | Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended. |
| CRITICAL | 7.5 – 10 | Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision. |
Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.